In vitro construction of effective M1GS ribozymes targeting HCMV UL54 RNA segments

Acta Biochimica et Biophysica Sinica

Volumn 37, Issue 3, 2005, Pages 210-214

  Su, Yun Zhen ^a   Li, Hong Jian ^a   Li, Yue Qin ^a   Chen, Hao Jun ^a   Tang, Dong Sheng ^a   Zhang, Xin ^a   Jiang, Hong ^a   Zhou, Tian Hong ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

DNA polymerase; Guide sequence; HCMV; Ribonuclease P (RNase P)

Indexed keywords

MESSENGER RNA; NUCLEOTIDE; RIBONUCLEASE; RIBONUCLEASE P; RIBOZYME; VIRUS ENZYME; VIRUS RNA;

ARTICLE; BIOTECHNOLOGY; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME DEGRADATION; ENZYME ENGINEERING; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; PROTEIN TARGETING; RNA SEQUENCE; RNA TRANSCRIPTION; TERMINAL SEQUENCE; UL54 GENE; VIRUS GENE;

ESCHERICHIA COLI; HUMAN HERPESVIRUS 5;

EID: 19344368309     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2005.00025.x     Document Type: Article

References (14)

1. Lewin AS, Hauswirth WW. Ribozyme gene therapy: Applications for molecular medicine. Trends Mol Med, 2001, 7(5): 221-228
2. Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ. Therapeutic applications of ribozymes. Pharmacol Ther, 1995, 68(2): 247-267
3. Raj SML, Liu FY. Engineering of RNase P ribozyme for gene-targeting applications. Gene, 2003, 313(2003): 59-69
4. Trang P, Hsu AW, Liu FY. Nuclease footprint analyses of the interactions between RNase P ribozyme and a model mRNA substrate. Nucleic Acids Res, 1999, 27(23): 4590-4597
5. Kilani AF, Trang P, Jo S, Hsu A, Kim J, Nepomuceno E, Liou K et al. RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture. J Biol Chem, 2000, 275(14): 10611-10622
6. Trang P, Lee M, Nepomuceno E, Kim J, Zhu H, Liu FY. Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli. Proc Natl Acad Sci USA, 2000, 97(11): 5812-5817
7. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol, 2004, 65(5): 403-409
8. Trang P, Kim K, Liu F. Developing RNase P ribozymes for gene-targeting and antiviral therapy. Cell Microbiol, 2004, 6(6): 499-508
9. Zou J, Gong ZX. Inhibtion of replication of goose paramyxovirus SF02 by hammerhead ribozyme targeting to the SF02 F mRNA in chicken embryo fibroblasts. Acta Biochim Biophys Sin, 2003, 35(9): 801-805
10. Zheng WC, Qi GR. tRNA-embedded hammerhead ribozymes mediate destruction of HBV (subtype adr) in vitro. Acta Biochim Biophys Sin, 1998, 30(5): 432-438
11. Brannvall M, Mattsson JG, Svard SG, Kirsebom LA. RNase P RNA structure and cleavage reflect the primary structure of tRNA genes. J Mol Biol, 1998, 283(4): 771-783
12. Kufel J, Kirsebom LA. Different cleavage sites are aligned differently in the active site of M1 RNA, the catalytic subunit of Escherichia coli RNase P. Proc Natl Acad Sci USA, 1996, 93(12): 6085-6090
13. Kawa D, Liu FY, Yuan Y, Liu F. Inhibition of viral gene expression by human ribonuclease P. RNA, 1998, 4(11): 1397-1406
14. Li Y, Guerrier-Takada CG, Altman S. Targeted cleavage of mRNA in vitro by RNase P from Escheichia coli. Proc Natl Acad Sci USA, 1992, 89(8): 3185-3189